Best for
Mobile
How to buy Aeglea BioTherapeutics shares
Own Aeglea BioTherapeutics shares in just a few minutes.
Aeglea BioTherapeutics, Inc is a biotechnology business based in the US. Aeglea BioTherapeutics shares (AGLE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Aeglea BioTherapeutics employs 87 staff and has a market cap (total outstanding shares value) of $365.8 million.
How to buy shares in Aeglea BioTherapeutics
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: AGLE in this case.
- Research Aeglea BioTherapeutics shares. The platform should provide the latest information available.
- Buy your Aeglea BioTherapeutics shares. It's that simple.
What's in this guide?
- Can I buy shares in Aeglea BioTherapeutics?
- Aeglea BioTherapeutics shares summary
- Compare share dealing platforms
- Is Aeglea BioTherapeutics stock a buy or sell?
- Can I short Aeglea BioTherapeutics shares?
- Aeglea BioTherapeutics's financials
- How volatile are Aeglea BioTherapeutics shares?
- Does Aeglea BioTherapeutics pay a dividend?
- Other common questions
Aeglea BioTherapeutics share price
Use our graph to track the performance of AGLE stocks over time.Aeglea BioTherapeutics shares at a glance
Information last updated 2021-01-23.
| Latest market close | $N/A |
|---|---|
| 52-week range | $3.5 - $11.38 |
| 50-day moving average | $8.173 |
| 200-day moving average | $7.8288 |
| Wall St. target price | $15.63 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.299 |
Invest in Aeglea BioTherapeutics shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Go to site
Capital at risk
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Aeglea BioTherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Aeglea BioTherapeutics financials
| Gross profit TTM | $-64,600,000 |
|---|---|
| Return on assets TTM | -39.4% |
| Return on equity TTM | -73.75% |
| Profit margin | 0% |
| Book value | $3.049 |
| Market capitalisation | $365.8 million |
TTM: trailing 12 months
How to short and sell Aeglea BioTherapeutics shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "AGLE.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 1.8 million Aeglea BioTherapeutics shares held short by investors – that's known as Aeglea BioTherapeutics's "short interest". This figure is 4.6% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Aeglea BioTherapeutics shares can be evaluated.
Aeglea BioTherapeutics's "short interest ratio" (SIR)
Aeglea BioTherapeutics's "short interest ratio" (SIR) is the quantity of Aeglea BioTherapeutics shares currently shorted divided by the average quantity of Aeglea BioTherapeutics shares traded daily (recently around 231038.0952381). Aeglea BioTherapeutics's SIR currently stands at 7.98. In other words for every 100,000 Aeglea BioTherapeutics shares traded daily on the market, roughly 7980 shares are currently held short.
However Aeglea BioTherapeutics's short interest can also be evaluated against the total number of Aeglea BioTherapeutics shares, or, against the total number of tradable Aeglea BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aeglea BioTherapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aeglea BioTherapeutics shares in existence, roughly 40 shares are currently held short) or 0.041% of the tradable shares (for every 100,000 tradable Aeglea BioTherapeutics shares, roughly 41 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aeglea BioTherapeutics.
Find out more about how you can short Aeglea BioTherapeutics stock.
Aeglea BioTherapeutics share dividends
We're not expecting Aeglea BioTherapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Aeglea BioTherapeutics share price volatility
Over the last 12 months, Aeglea BioTherapeutics's shares have ranged in value from as little as $3.5 up to $11.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea BioTherapeutics's is 1.6606. This would suggest that Aeglea BioTherapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Aeglea BioTherapeutics overview
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Frequently asked questions
More guides on Finder
-
How to buy Aeglea BioTherapeutics shares
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Charlie’s Holdings shares
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Lemonade shares
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Unity Software shares
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
-
How to buy FuelCell Energy shares
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Aeglea BioTherapeutics shares
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
-
How to buy Zomedica Pharmaceuticals shares
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
-
How to buy YRC Worldwide shares
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
-
How to buy Xeros Technology Group shares
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
-
How to buy Xpediator shares
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ask an Expert